In a patient with a history of hepatitis C infection who now has a dipstick finding of 2+ proteinuria, what differential diagnoses and management steps should be considered?

Evaluation of 2+ Proteinuria in a Patient with Past HCV Infection

In a patient with past HCV infection presenting with 2+ proteinuria, you must first confirm active HCV viremia with nucleic acid testing (NAT), as HCV-associated glomerulonephritis can persist or develop even after apparent viral clearance, and this finding may represent immune-complex mediated kidney disease requiring specific treatment. 1

Immediate Diagnostic Steps

Confirm HCV Status and Quantify Proteinuria

• Check HCV RNA by NAT immediately to determine if this is active infection versus true sustained virologic response (SVR), as patients with "past" HCV may have ongoing viremia 1
• Quantify proteinuria with either:
  • Urine protein-creatinine ratio (UPCR) on a spot urine sample, or
  • 24-hour urine protein collection 1
• A dipstick 2+ typically corresponds to approximately 100 mg/dL, but quantification is essential for management decisions 1

Assess Kidney Function and Disease Severity

• Measure serum creatinine and calculate eGFR to determine CKD stage 1
• Perform urinalysis with microscopy looking for:
  • Red blood cells and red cell casts (suggesting active glomerulonephritis)
  • White blood cells
  • Cellular casts 1
• Check for systemic signs of cryoglobulinemia: purpura, arthralgias, weakness, as these indicate cryoglobulinemic vasculitis requiring urgent treatment 1

Key Differential Diagnoses to Consider

HCV-Associated Glomerulonephritis (Most Important)

• Membranoproliferative glomerulonephritis (MPGN) is the most common renal lesion in HCV infection, occurring with or without cryoglobulinemia 2, 3
• HCV-infected patients have significantly higher rates of proteinuria (10.2%) compared to non-infected individuals (7.0%) 4
• Up to 50% of patients with HCV-associated renal disease present with renal insufficiency, and 25% present with nephrotic syndrome 2
• Cryoglobulinemia occurs in approximately 59% of HCV patients with glomerulonephritis, though only 44% have extrarenal manifestations 3

Other Causes to Exclude

• Diabetes mellitus (the most important risk factor for proteinuria overall) 4
• Hypertension (second most important risk factor) 4
• Other glomerular diseases if presentation is atypical 1

When to Perform Kidney Biopsy

The KDIGO 2022 guidelines provide clear criteria for when biopsy is needed versus when you can proceed without it:

You CAN manage WITHOUT biopsy if: 1

• Typical presentation of immune-complex proliferative glomerulonephritis
• Stable kidney function
• No nephrotic syndrome
• Clinical picture consistent with HCV-associated disease

You MUST perform biopsy (with immunofluorescence and electron microscopy) if: 1

• Atypical presentation
• Rapidly progressive glomerulonephritis (RPGN)
• Cryoglobulinemic flare
• eGFR or proteinuria continues to deteriorate despite achieving SVR
• New-onset proteinuria with UPCR >1 g/g or 24-hour protein >1 g on 2+ occasions (especially in transplant recipients) 1

Treatment Algorithm Based on Clinical Presentation

If Active HCV Viremia is Present:

For stable kidney function WITHOUT nephrotic syndrome: 1

• Treat with direct-acting antivirals (DAAs) as first-line therapy before considering other treatments
• For CKD stages 4-5 (including dialysis): use elbasvir/grazoprevir or glecaprevir/pibrentasvir 5, 6
• For CKD stages 1-3: sofosbuvir-based regimens are appropriate 5, 6

For cryoglobulinemic flare or RPGN: 1

• Treat with BOTH DAAs AND immunosuppressive agents ± plasma exchange
• Rituximab is the first-line immunosuppressive agent 1

For nephrotic syndrome: 1

• Decision regarding immunosuppression must be made based on severity and rate of progression
• Consider biopsy to guide therapy

If SVR Already Achieved (True Past Infection):

This scenario requires careful evaluation because: 1

• Proteinuria developing or persisting after SVR suggests either:
  • Incomplete viral clearance (recheck NAT)
  • Ongoing immune-mediated injury despite viral clearance
  • Alternative cause of kidney disease

Management approach: 1

• If proteinuria worsens despite documented SVR: perform kidney biopsy
• If biopsy shows histologically active HCV-associated glomerulonephritis not responding to prior antiviral therapy: use immunosuppressive therapy, with rituximab as first-line 1

Critical Pitfalls to Avoid

• Do not assume "past HCV" means no active viremia – always confirm with NAT, as serologic tests remain positive after clearance 1
• Do not delay DAA treatment in patients with active HCV and glomerulonephritis, as treatment can reverse kidney disease 1, 3
• Do not use immunosuppression alone in active HCV infection without concurrent DAA therapy, as this can worsen viremia 1
• Do not dismiss proteinuria as benign in HCV patients – approximately 10% progress to end-stage renal disease 2
• Do not forget to screen for cryoglobulins even in the absence of classic extrarenal manifestations 3

Additional Workup

• Hepatitis B surface antigen (HBsAg) to exclude coinfection 7
• HIV testing as coinfection accelerates liver fibrosis and affects treatment decisions 7
• Liver function tests and assessment of liver fibrosis using noninvasive markers 7
• Renal ultrasound to assess kidney size and exclude structural abnormalities 8